Domača stranAYJ • FRA
add
Valneva SE
Prejšnji trg. dan.
2,76 €
Dnevni razpon
2,72 € - 2,79 €
Letni razpon
1,74 € - 4,20 €
Tržna kapitalizacija
468,62 mio. EUR
Povprečni obseg
8,64 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
EPA
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(EUR) | mar. 2025info | Sprememba L/L |
---|---|---|
Prihodek | 49,23 mio. | 50,31 % |
Stroški poslovanja | 17,20 mio. | 124,31 % |
Čisti dohodek | −9,23 mio. | −115,67 % |
Čista dobičkovnost prihodkov | −18,75 | −110,42 % |
Earnings per share | −0,14 | −115,41 % |
EBITDA | −2,28 mio. | −103,21 % |
Efektivna davčna stopnja | −19,00 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
(EUR) | mar. 2025info | Sprememba L/L |
---|---|---|
Denar. in kratkor. naložbe | 152,99 mio. | −13,39 % |
Skupna sredstva | 482,24 mio. | −4,09 % |
Skupne obveznosti | 306,99 mio. | −2,11 % |
Celoten lastniški kapital | 175,25 mio. | — |
Shares outstanding | 153,87 mio. | — |
Razmerje P/B | 2,42 | — |
Donosnost sredstev | −3,03 % | — |
Donosnost kapitala | −3,80 % | — |
Denarni tok
Neto sprememba denarnih sredstev
(EUR) | mar. 2025info | Sprememba L/L |
---|---|---|
Čisti dohodek | −9,23 mio. | −115,67 % |
Denar iz dejavnosti | −8,15 mio. | 71,34 % |
Denar iz naložb | −961,00 tis. | −101,11 % |
Denar iz financiranja | −5,58 mio. | 25,14 % |
Neto sprememba denarnih sredstev | −15,28 mio. | −130,22 % |
Prost denarni tok | −19,68 mio. | −198,73 % |
Vizitka
Valneva SE is a speciality vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company current market three proprietary travel vaccines.
Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats.
Valneva has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States. Wikipedia
Generalni direktor
Datum ustanovitve
2013
Spletno mesto
Zaposleni
713